Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: Seven-Market Drug Forecast and Market Analysis

• The use of GLP-1R agonists is expected to quadruple in the next 10 years, at a CAGR of 14.9%. The GLP-1R agonists market across the 7MM was valued at $31.3 billion in 2023, and it is projected to reach $125.3 billion by 2033. At present, GLP-1R agonists are approved for type 2 diabetes and obesity. They can be used as second-line therapies if metformin pharmacotherapy is not enough in type 2 diabetes management, and after lifestyle modifications have not been effective in reducing weight in obesity patients. The GLP-1R agonists marketed for type 2 diabetes are Ozempic (semaglutide), Rybelsus (semaglutide), Trulicity (dulaglutide), Victoza (liraglutide), Mounjaro (tirzepatide), Xultophy (liraglutide + insulin), Suliqua (lixisenatide + insulin), Bydureon (exenatide), Byetta (exenatide), and Lyxumia (lixisenatide)
• The GLP-1R agonists marketed for obesity are Saxenda (liraglutide), Wegovy (semaglutide), and Mounjaro/Zepbound (tirzepatide).
• The major unmet needs in the GLP-1R agonist space currently are costs, long-term adherence and tolerability, drug availability, and physician awareness.
• There are multiple GLP-1R agonist-based therapies in late-stage clinical development for type 2 diabetes or obesity, including combination therapies and novel dual and triple agonists.
• The major market driver in the 7MM will be the increased patient population and increased awareness of and confidence in this relatively new drug class.

Key Highlights

• Report deliverables include a Pdf and Excel-based forecast model. Forecast includes US, 5EU, and Japan.
• Forecast covers the period 2023-2033.
• 2023 base year sales within the GLP-1R agonists market are approximately $31.3billion across the 7MM detailed in this report. The analyst estimates that the GLP-1R agonist market will grow at a compound annual growth rate (CAGR) of 14.9% to reach $125 billion by the end of the forecast period.

Scope

• Overview of GLP-1R agonists, type 2 diabetes and obesity, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized GLP-1R agonists therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the GLP-1R agonists market.
• Pipeline analysis: comprehensive data assessing emerging trends and dual/triple mechanisms of action under development for tye 2 diabetes and obesity medicines with a GLP-1R agonist action. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 7MM GLP-1R agonists therapeutics type 2 diabetes and obesity market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM GLP-1R agonists therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM GLP-1R agonists therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.